CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- 4 Open-market sale Chief Executive Officer sold 9,798 shares at $52.80 ($517,334)
- 4 Open-market sale Chief Executive Officer sold 6,967 shares at $52.58 ($366,325)
- 4 Open-market sale General Counsel and Secretary sold 2,112 shares at $52.58 ($111,049)
- 4 Open-market buy Chief Medical Officer bought 1,508 shares at $32.96 ($49,704)
- 4 Planned sale Chief Financial Officer sold 34,972 shares at $60.19 ($2,104,965)
- 4 Planned sale Chief Executive Officer sold 90,000 shares at an average $57.40 ($5,166,298)
- 4 Planned sale Chief Financial Officer sold 29,700 shares at an average $60.16 ($1,786,636)
- 4 Planned sale Chief Financial Officer sold 10,000 shares at an average $55.95 ($559,549)
- 4 Gift Chief Executive Officer gave 30,000 shares (gift)
- 4 Open-market sale Chief Executive Officer sold 50,895 shares at $67.91 ($3,456,279)
- 4 Open-market sale Chief Executive Officer sold 4,242 shares at $66.60 ($282,517)
- 4 Open-market sale General Counsel and Secretary sold 1,076 shares at $66.60 ($71,662)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Gift Chief Executive Officer gave 6,000 shares (gift)
- 4 Open-market sale Chief Executive Officer sold 13,081 shares at $58.15 ($760,660)
- 4 Open-market buy Director bought 20,000 shares at $57.03 ($1,140,600)
- 4 Open-market buy Director bought 989,812 shares at $52.03 ($51,499,918)
Page 3 of 26 · 502 filings